FDA Requests $4.03 Billion for FY2011-a 23% Increase
The US Food and Drug Administration is requesting $4.03 billion to promote and protect public health as part of the President's fiscal year 2011 budget?a 23% increase over the agency?s current $3.28 billion budget.
The US Food and Drug Administration is requesting $4.03 billion to promote and protect public health as part of the President's fiscal year 2011 budget-a 23% increase over the agency's current $3.28 billion budget.
The FY 2011 request, which covers the period of Oct 1, 2010, through Sept 30, 2011, includes increases of $146 million in budget authority and $601 million in industry user fees. The budget for biologics has been increased by $23 million, to $329 million.
The budget request reflects the FDA's resolve to transform food safety practices, improve medical product safety, protect patients, and modernize FDA regulatory science to advance public health. The funding request also supports new regulatory authority to regulate cigarettes and other tobacco products received in June 2009.
The proposed budget includes support for the FDA's investment in addressing the challenges of the 21st century. The FDA envisions a transformed US food safety system that focuses on prevention, increased efforts to address medical product safety challenges, and a focus on modernizing regulatory science at the FDA.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
